# Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome

> **NCT05330845** · NA · TERMINATED · sponsor: **Centre Hospitalier Henri Duffaut - Avignon** · enrollment: 35 (actual)

## Conditions studied

- COVID-19 Acute Respiratory Distress Syndrome

## Interventions

- **BIOLOGICAL:** IL6 assessment
- **BIOLOGICAL:** CRP and PCT assessment

## Key facts

- **NCT ID:** NCT05330845
- **Lead sponsor:** Centre Hospitalier Henri Duffaut - Avignon
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-05
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-12-31
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** end of recruitment period
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05330845

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05330845, "Interleukine 6 (IL6) Assay for Predicting Failure of Spontaneous Breathing in Patients With COVID-19 Acute Respiratory Distress Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05330845. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*